Latest news
Pancreatic Cancer Is Forcing Regulators to Move Faster
EMA has started a phased review of daraxonrasib in pancreatic cancer, while Revolution Medicines says its U.S. rolling NDA is nearing completion. The science is moving into the regulatory fast lane. Access systems are not ready yet.
Huntington’s Gets Another Chance at Proof
Ebola May Be Reaching Kisangani. Containment Cannot Stay Provincial.
New global heart failure definition exposes a policy gap: systems still diagnose too late and treat too narrowly
Sugar substitutes were sold as metabolic shortcuts. The evidence is getting harder to ignore
Early Lung Cancer Just Became a Biomarker Test of the System
Pancreatic Cancer’s ADC Moment Will Live or Die by the Biomarker
Duchenne Evidence Moves Into the Muscle
Moldova Is Taking Vaccines To Roma Communities. Respect Is Part Of Delivery.
Merck KGaA’s Saturnus Bio bet signals a shift to genotype-driven cardiology, and a looming readiness gap for health systems
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.